Sai Parenterals Ltd IPO - Check Issue Date, Price, Lot Size & Details with BlinkX.

Sai Parenterals Ltd IPO

Our Company is a diversified pharmaceutical formulations company with capabilities in research, development and manufacturing. We are in the business of (i) Branded Generic Formulations and (ii) Contract Development and Manufacturing Organisation (CDMO) products and services for the domestic and international markets. Our Company's portfolio includes formulation products across various therapeutic areas like cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology with offerings across dosage forms such as injectables, tablets, capsules, liquid orals and ointments. In the injectables segment, we have capabilities in sterile manufacturing for critical care and antibiotics, which are delivered through dry powder injections, pre-filled syringes, ampoules, and vials.

Sai Parenterals Ltd IPO Details

Total Shares Offered

₹ 1,04,28,288

Offer to Public

31,57,880

Retail Max (Shares)

₹ 36,49,901

Pre Issue Promoters Holding

₹ 2,26,00,001

Exchange

BSE

Issue size

₹ 408.79 Cr

IPO Open Date

Mar 24, 2026

Close Date

Mar 27, 2026

Lot Size

Min Investment

₹ 14,136

Issue Type

Book Building

Listing Date

Apr 2, 2026

Sai Parenterals Ltd IPO Dates

Mar 24, 2026

Opening date

Mar 27, 2026

Closing date

Mar 30, 2026

Basis of Allotment

Apr 1, 2026

Initiation of Refunds

Apr 1, 2026

Credit of Shares

Apr 2, 2026

Listing date

Details

Sector	Type
Sector	Pharmaceuticals - Indian - Formulations
Sub Sector	NA
Issue Type	Book Building

Subscription Status

*Values are in Lakhs

Investor Type	Subscription Times	Shares Offered*
QIB	0x	5214144
NII	0x	1564243
Retail	0x	3649901
Employee	0x	0
Total	0x	10428288

Investor Type

QIB

NII

Retail

Employee

Total

Subscription Times

5214144

1564243

3649901

10428288

Sai Parenterals Ltd Financial Status

Income Statement

Particulars (In Rs. Crores)

Balance Sheet

Particulars (In Rs. Crores)

Particulars (in Rs. Crores)	FY23	FY22	FY21
Revenue from operations	TBA	TBA	TBA
EBITDA	TBA	TBA	TBA
PAT	TBA	TBA	TBA
Total Assets	TBA	TBA	TBA
Share Capital	TBA	TBA	TBA
Total Borrowings	TBA	TBA	TBA
Operating Activities (Net Cash)	TBA	TBA	TBA
Investing Activities (Net Cash)	TBA	TBA	TBA
Financing Activities (Net Cash)	TBA	TBA	TBA
Net Cashflow	TBA	TBA	TBA

About Sai Parenterals Ltd

Our Company was originally incorporated as `Sai Parenteral's Private Limited', a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated January 12, 2001, issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. Thereafter, our Company was converted into a public limited company pursuant to resolution of our Board dated December 24, 2021 and a special resolution of our Shareholders dated January 05, 2022, and consequently, the name of our Company was changed to `Sai Parenteral's Limited' and a fresh certificate of incorporation consequent upon conversion to public limited company dated January 17, 2022, was issued to our Company by the RoC.

The Indian pharmaceutical industry is the world's third largest by volume and was estimated at $62 billion in 2025. It is expected to grow at a CAGR of 11.2% to reach $146 billion by 2033. The Indian drug formulation market, estimated at $47 billion in 2025, is projected to reach $109 billion by 2033, reflecting a robust CAGR of 11.2% over the period. Indian CDMOs are increasingly participating in larger parts of the pharma value chain, from drug discovery to commercialisation across multiple geographies, in response to evolving trends in the global pharmaceutical industry. Indian CDMO segment to sustain its strong growth trajectory over the next 10 years.

Peer Comparison:

Sai Parenteral's Limited
Sai Life Sciences Limited
Innova Captab Limited
Senores Pharmaceuticals Limited
Gland Pharma Limited

Sai Parenterals Ltd Key Points

Strengths

Diversified generic formulations player with an established track record.

Strategically located and accredited Manufacturing Facilities.

Strong focus on CDMO business.

Well-established sales network in India and overseas.

Track record of value-accretive acquisitions.

Risk

The company's Manufacturing Facilities are concentrated in Hyderabad, Telangana and Ongole, Andhra Pradesh. The company is exposed to risks originating from slowdown or shutdown, economic, regulatory, political and other changes in this region, including natural disasters, which could adversely affect its business, results of operations and financial condition.

Out of its diversified product portfolio, approximately 44.78%, 47.64% and 92.03% during the Fiscals 2025, 2024 and 2023, respectively of the company's Net Revenue from Operations was derived from the sale of injectables. Any reduction in demand for these products may adversely affect its business, financial condition, results of operations and cash flows.

The company's Manufacturing Facilities are subject to periodic inspections and audits by regulatory authorities and customers. The company may be subject to regulatory action which may damage its reputation, leading to an adverse effect on the company's business, results of operations, financial condition and cash flows.

Strategy

Expansion into global injectable formulations market.

Capitalise on CDMO opportunity by leveraging our manufacturing capabilities with enhanced R&D competences.

Strengthening our presence in Regulated Markets through the upcoming Noumed's manufacturing facility at Adelaide, Australia.

Focus on new product development to drive future growth.

Grow our Branded Generic Formulations business by leveraging opportunities in the international markets.

How To Apply for Sai Parenterals Ltd IPO Online?

Step 1:

Step 2:

From the list of open IPOs, select the IPO you want to invest.

Step 3:

Go through the IPO details like lot size, price band, about the company, etc.

Step 4:

Click ‘Apply IPO’ to apply and enter the number of lots and bidding price along with your UPI ID.

Step 5:

Confirm your bid and accept the payment mandate sent to your UPI App for completing the IPO application.

FAQs on IPO (Initial Public Offering)

What is the issue size of the Sai Parenterals Ltd IPO?

Sai Parenterals Ltd's IPO offers shares for up to 285 It begins on Mar 24, 2026 and ends on Mar 27, 2026.

What is the price of the Sai Parenterals Ltd IPO?

The price of Sai Parenterals Ltd IPO ranges between ₹372 to ₹392 per share.

What are the open and close dates for the Sai Parenterals Ltd IPO?

The Sai Parenterals Ltd IPO opens on Mar 24, 2026 and closes on Mar 27, 2026.

When will the Sai Parenterals Ltd IPO be allotted?

The allotment for the Sai Parenterals Ltd IPO will be finalised on Mar 30, 2026. The shares will be listed on BSE and NSE on Apr 2, 2026.

What is the minimum lot size required for Sai Parenterals Ltd IPO?

The minimum lot size for Sai Parenterals Ltd IPO is 38 shares, priced between ₹372 to ₹392 per share.

What is the GMP of Sai Parenterals Ltd IPO?

The GMP (Grey Market Premium) of Sai Parenterals Ltd IPO fluctuates based on market demand and sentiment.

How do you check the allotment status of Sai Parenterals Ltd IPO?

To check the allotment status of Sai Parenterals Ltd IPO, visit the registrar's website, select the IPO, enter your PAN Card number, Application Number, or DP Client ID, and click 'search.'

Where is the Sai Parenterals Ltd IPO getting listed?

The Sai Parenterals Ltd IPO is getting listed on the BSE and NSE. Bidding opens on Mar 24, 2026, and closes on Mar 27, 2026. The allotment is finalised on Mar 30, 2026.

How do you apply for the Sai Parenterals Ltd IPO?

To apply for the Sai Parenterals Ltd IPO, download the BlinkX app, complete KYC, select the IPO, enter bid details, and submit. Verify UPI payment for shares allotment.